Table 1.
Patients and controls
| Remission | Smouldering | DC | HBD | |
|---|---|---|---|---|
| Total no. | 44 | 15 | 48 | 30 |
| No. MPO/PR3/MPO + PR3 (n) | 15/28/1 | 8/7/0 | – | – |
| No. females/males (n) | 21/23 | 5/10 | 17/31 | |
| Age (years) | 57 (22–84) | 63 (27–82) | 51 (21–81) | – |
| Relapses in 6 years (n) | 18 | 8 | – | – |
| Severe outcome (n) | 9 | 15 | – | – |
| Cystatin C (mg/ml) | 1·5 (0·4–4·6) | 1·9 (0·8–5·1) | 1·5 (0·7–5·3) | 0·7 (0·4–1·2) |
| BVAS | 0–1 | 2–5 | – | – |
HBD = healthy blood donors, DC = disease controls. MPO = anti myeloperoxidase-ANCA positive patients, PR3 = anti proteinase 3-ANCA positive patients, MPO + PR3 = double positive patients. Severe outcome = severe organ damage, start in dialysis or death due to vasculitic complications during 6 years follow-up. BVAS = Birmingham vasculitis activity score.